Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Ian

Showing results (61-70 of 120) with videos related to

Pageof 12
Sort By:
Cancer|April 10, 2004
Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium TrialSusan M Chang, Michael D Prados, W K Alfred Yung, et al.
Neuro-Oncology|March 5, 2010
Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)Fabio M Iwamoto, Kathleen R Lamborn, H Ian Robins, et al.
Neuro-Oncology|October 21, 2020
A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymomaMark R Gilbert, Ying Yuan, Jimin Wu, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 2008
Prospective evaluation of quality of life and neurocognitive effects in patients with multiple brain metastases receiving whole-brain radiotherapy with or without thalidomide on Radiation Therapy Oncology Group (RTOG) trial 0118Benjamin W Corn, Jennifer Moughan, Jonathan P S Knisely, et al.
Journal of Neuro-Oncology|October 14, 2008
A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomasNicholas Butowski, Kathleen R Lamborn, Bee L Lee, et al.
Neuro-Oncology|January 30, 2021
Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825)Jeffrey S Wefel, Terri S Armstrong, Stephanie L Pugh, et al.
Targeted Oncology|January 25, 2013
Cytokines associated with toxicity in the treatment of recurrent glioblastoma with afliberceptNicole Shonka, Yuji Piao, Mark Gilbert, et al.
Cancer|August 27, 2015
Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non-small cell lung cancerLakshmi Nayak, Lisa M DeAngelis, H Ian Robins, et al.
Investigational New Drugs|July 14, 2005
Phase II study of CCI-779 in patients with recurrent glioblastoma multiformeSusan M Chang, Patrick Wen, Timothy Cloughesy, et al.
Journal of Neuro-Oncology|February 16, 2015
Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 studyMinesh P Mehta, Ding Wang, Fen Wang, et al.
Pageof 12

Showing results (61-70 of 120) with videos related to

Sort By:
Pageof 12
Cancer|April 10, 2004
Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium TrialSusan M Chang, Michael D Prados, W K Alfred Yung, et al.
Neuro-Oncology|March 5, 2010
Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)Fabio M Iwamoto, Kathleen R Lamborn, H Ian Robins, et al.
Neuro-Oncology|October 21, 2020
A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymomaMark R Gilbert, Ying Yuan, Jimin Wu, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 2008
Prospective evaluation of quality of life and neurocognitive effects in patients with multiple brain metastases receiving whole-brain radiotherapy with or without thalidomide on Radiation Therapy Oncology Group (RTOG) trial 0118Benjamin W Corn, Jennifer Moughan, Jonathan P S Knisely, et al.
Journal of Neuro-Oncology|October 14, 2008
A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomasNicholas Butowski, Kathleen R Lamborn, Bee L Lee, et al.
Neuro-Oncology|January 30, 2021
Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825)Jeffrey S Wefel, Terri S Armstrong, Stephanie L Pugh, et al.
Targeted Oncology|January 25, 2013
Cytokines associated with toxicity in the treatment of recurrent glioblastoma with afliberceptNicole Shonka, Yuji Piao, Mark Gilbert, et al.
Cancer|August 27, 2015
Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non-small cell lung cancerLakshmi Nayak, Lisa M DeAngelis, H Ian Robins, et al.
Investigational New Drugs|July 14, 2005
Phase II study of CCI-779 in patients with recurrent glioblastoma multiformeSusan M Chang, Patrick Wen, Timothy Cloughesy, et al.
Journal of Neuro-Oncology|February 16, 2015
Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 studyMinesh P Mehta, Ding Wang, Fen Wang, et al.
Pageof 12